Schaeffer's Top Stock Picks for '25

JPMorgan Says Drug Stock Can't Live Up to High Expectations

This marks the first equivalent of a "sell" rating on MRTX

Aug 2, 2019 at 10:19 AM
facebook X logo linkedin


Mirati Therapeutics Inc (NASDAQ:MRTX) shares have had a huge year, rallying from the low $40 area to a record high of $111.99 on July 31. However, the cancer drug producer has shed 4.9% today to trade at $99.47, following a bear note out of J.P. Morgan Securities. The brokerage firm downgraded its view on MRTX to "underweight" from "neutral," and dropped its price target by $16 to $85, citing expectations that are too high around the company's MRTX849 drug, which is being tested to treat colorectal and lung cancer patients. The analyst in coverage said the current stock price doesn't reflect the short-term risks around Mirati.

Surely, most other analysts have been bullish on MRTX shares, and today's note from J.P. Morgan Securities actually represents the first equivalent of a "sell" to hit the book. By the numbers, seven of the other 12 covering brokerage firms consider the stock a "strong buy."

Many other traders have already been upping the bearish ante on the oncology specialist. That is, short interest increased over 26% in the last two reporting periods. Almost 24% of the total float is now dedicated to short interest, and it would take these bears more than eight days to cover their positions.

And while the security sees little absolute volume in the options pits, those who have taken positions on Mirati Therapeutics have been notably put-skewed. The equity's current Schaeffer's put/call open interest ratio (SOIR) comes in at 1.43, and ranks in the 98th annual percentile.

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?

 

 

(function(doc, script) { var js, fjs = doc.getElementsByTagName(script)[0], frag = doc.createDocumentFragment(), add = function(url, id) { if (doc.getElementById(id)) {return;} js = doc.createElement(script); js.src = url; id && (js.id = id); frag.appendChild( js ); }; // Google+ button //add('https://apis.google.com/js/platform.js', async="defer"); // Facebook SDK add('//connect.facebook.net/en_US/all.js#xfbml=1&appId=772755279557744', 'facebook-jssdk'); // Twitter SDK //add('//platform.twitter.com/widgets.js', charset='utf-8'); fjs.parentNode.insertBefore(frag, fjs); }(document, 'script'));